Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€4.86
Target price
20.11.24
€9.15
Performance (%)
17.42%
Price
28.06.24
€5.78
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ currently has a performance of 17.42%. This prediction currently runs until 20.11.24. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Biocryst Pharmaceuticals | -3.471% | -3.471% |
iShares Core DAX® | 0.238% | -2.265% |
iShares Nasdaq 100 | -0.304% | 5.808% |
iShares Nikkei 225® | 2.271% | 1.577% |
iShares S&P 500 | -0.296% | 4.447% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat